Silverarc Capital Management LLC Has $10.03 Million Stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Silverarc Capital Management LLC reduced its holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 19.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 598,952 shares of the company's stock after selling 145,640 shares during the period. Centessa Pharmaceuticals makes up about 2.2% of Silverarc Capital Management LLC's investment portfolio, making the stock its 14th largest position. Silverarc Capital Management LLC owned about 0.45% of Centessa Pharmaceuticals worth $10,032,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. GAMMA Investing LLC grew its stake in shares of Centessa Pharmaceuticals by 29.1% in the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock worth $64,000 after acquiring an additional 865 shares during the last quarter. Barclays PLC boosted its holdings in Centessa Pharmaceuticals by 1,414.9% in the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after purchasing an additional 4,952 shares during the period. China Universal Asset Management Co. Ltd. grew its position in Centessa Pharmaceuticals by 39.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company's stock worth $317,000 after purchasing an additional 5,316 shares during the last quarter. XTX Topco Ltd grew its position in Centessa Pharmaceuticals by 122.9% in the 4th quarter. XTX Topco Ltd now owns 22,680 shares of the company's stock worth $380,000 after purchasing an additional 12,506 shares during the last quarter. Finally, State Street Corp bought a new position in shares of Centessa Pharmaceuticals during the 3rd quarter worth about $777,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on CNTA shares. TD Cowen started coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a "buy" rating on the stock. Piper Sandler started coverage on Centessa Pharmaceuticals in a research report on Monday, March 31st. They set an "overweight" rating and a $38.00 price objective on the stock. Guggenheim restated a "buy" rating and issued a $28.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Finally, Morgan Stanley restated an "overweight" rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Centessa Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $27.71.

Centessa Pharmaceuticals Price Performance

NASDAQ:CNTA traded up $0.18 during trading hours on Friday, reaching $13.79. The company had a trading volume of 480,936 shares, compared to its average volume of 605,883. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock has a 50-day moving average of $14.42 and a two-hundred day moving average of $15.87. Centessa Pharmaceuticals plc has a one year low of $7.75 and a one year high of $19.09. The firm has a market capitalization of $1.84 billion, a PE ratio of -9.01 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its earnings results on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.04. Analysts forecast that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 55,000 shares of the business's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $15.93, for a total value of $876,150.00. Following the transaction, the chief executive officer now owns 331,017 shares of the company's stock, valued at approximately $5,273,100.81. The trade was a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Iqbal J. Hussain sold 6,000 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $16.18, for a total value of $97,080.00. Following the sale, the general counsel now owns 105,386 shares in the company, valued at $1,705,145.48. The trade was a 5.39 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 225,566 shares of company stock valued at $3,690,409. 11.59% of the stock is currently owned by insiders.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.